Credit: Image Courtesy of Teri Boudreaux.
Teri Boudreaux was one of more than 5,000 women who joined a clinical trial that was looking at the benefit of adding the targeted therapy drug ribociclib to conventional hormonal therapy for the adjuvant treatment of HR-positive, HER2-negative early-stage breast cancer.